

10030877-042202 #710
10/030877/25102
531 Rec'd PCT/FT 19 OCT 2001

"EXPRESS MAIL CERTIFICATE"
"EXPRESS MAIL" MAILING LABEL NUMBER EV000521205US
DATE OF DEPOSIT 19 OCTOBER 2001

Attorney Docket No. P32293

INTERNATIONAL APP. NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/GB00/01522	19 April 2000	23 April 1999

TITLE OF INVENTION
NOVEL PHARMACEUTICAL

APPLICANT(S) FOR DO/US

Paul David James BLACKLER, Robert Gordon GILES, Stephen MOORE and Michael John SASSE

PRELIMINARY AMENDMENT

Preliminary to the examination of this application, Applicants respectfully request amendment of the above-identified application as follows:

In the Specification:

Kindly add the Abstract enclosed herewith on a separate sheet, at the end. ✓

In the Claims:

Please cancel claims 11-13. ✓

Please amend claims 1, 3-8, and 14 as follows: ✓

1. (Amended) A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt (the Polymorph) comprising:

- (i) an infra red spectrum containing peaks at 1752, 1546, 1154, 621, and 602 cm^{-1} ; and/or
- (ii) a Raman spectrum containing peaks at 1751, 1243 and 602 cm^{-1} ; and/or
- (iii) a solid-state nuclear magnetic resonance spectrum containing peaks at 111.9, 114.8, 119.6, 129.2, 134.0, 138.0, 144.7, 153.2, 157.1, 170.7, 170.7, 172.0 and 175.0 ppm; and/or
- (iv) an X-ray powder diffraction (XRPD) pattern which gives calculated lattice spacings of 6.46, 5.39, 4.83, 4.68, 3.71, 3.63, 3.58, and 3.48 Angstroms.

3. (Amended) A Polymorph according to claim 1, which provides a Raman spectrum substantially in accordance with Figure II.

4. (Amended) A Polymorph according to claim 1, which provides a solid-state nuclear magnetic resonance spectrum substantially in accordance with Figure III and/or Table I.